For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Preservation of Blood Pressure Stability with Hypertonic Mannitol during Hemodialysis InitiationMc Causland F.R.a, b · Prior L.M.d · Heher E.b, c · Waikar S.S.a, b
aRenal Division, Department of Medicine, Brigham and Women’s Hospital, bHarvard Medical School, and cDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Mass., USA; dUniversity College Dublin School of Medicine and Medical Science, Dublin, Ireland Corresponding Author
Finnian McCausland, MB, BCh
MRB-4, Brigham and Women’s Hospital
Boston, MA 02446 (USA)
Background: Intradialytic hypotensive events are common among hemodialysis patients and are associated with a variety of patient- and procedure-related factors, including intradialytic decline in plasma osmolality. Prior studies and practice have suggested that administration of osmotically active drugs may ameliorate blood pressure decline during chronic hemodialysis. Methods: Clinical and treatment data were collected for 102 consecutive patients requiring initiation of renal replacement therapy in 2 major teaching hospitals. Routine administration of mannitol differed according to institutional protocols, allowing its examination as the primary exposure of interest. Generalized linear models were fit to estimate associations of mannitol use during dialysis initiation with intradialytic blood pressure, as assessed by: (1) intradialytic blood pressure decline; (2) nadir intradialytic blood pressure; (3) absolute systolic blood pressure <90 mm Hg or decline >20 mm Hg. Results: Mean age was 62 years (±16), 70% were male and 44% were diabetic. Mean predialysis and nadir systolic blood pressure were 142 mm Hg (±29) and 121 mm Hg (±26), respectively. Mannitol administration was associated with a lesser decline in intradialytic blood pressure, a higher nadir blood pressure and fewer hypotensive events requiring intervention. No effect modification was evident according to diabetes or acuity of kidney disease (chronic vs. acute). Conclusions: Mannitol administration appears to preserve hemodynamic stability during hemodialysis initiation. Randomized controlled trials are needed to confirm these findings and identify optimal management strategies to prevent intradialytic hypotension.
© 2012 S. Karger AG, Basel
Since hemodialysis became available as a treatment modality, patients have experienced a myriad of adverse symptoms, often leading to reduced treatment efficacy and compliance. Advances in technology, dialysate composition and dialysis treatment prescriptions have only been partially successful in reducing the frequency and severity of these complaints. Intradialytic hypotensive events (IDH) in particular remain common, affecting up to one third of all chronic hemodialysis treatments [1,2,3]. IDH has been associated with the development of myocardial stunning , cerebral atrophy  and increased mortality  and may therefore represent an important modifiable risk factor in the hemodialysis population.
Early physicians noted an association between IDH and osmolality decline during hemodialysis; preliminary evidence suggested that administration of hyperosmolar fluid (e.g., hypertonic glucose or hypertonic saline) ameliorated excessive drops in blood pressure and other dialysis-associated symptoms, presumably by preventing net fluid movement from the intravascular to the intracellular compartments . However, many of these interventions resulted in unwanted side effects, including elevated blood sugar with hypertonic glucose, and increased thirst  and interdialytic weight gain  with hypertonic saline. Recent research has suggested that hyperosmolar fluid stimulates vasopressin release, which may have a direct effect on vascular tone, thereby providing an additional mechanism for intradialytic blood pressure support .
Mannitol is a six-carbon sugar derived from dextrose, with a molecular weight of 182 Da, undergoing predominantly renal clearance . Numerous historical studies have reported an association between the use of hypertonic mannitol and reduction of intradialytic symptoms and frequency of hypotensive events in chronic hemodialysis, with seemingly fewer reported side effects compared to other interventions [12,13,14]. However, these were generally small physiological studies limited by sample size. Despite promising results, mannitol is not routinely used in most centers to prevent excessive intradialytic blood pressure decline. We therefore investigated the potential benefit of mannitol administration during hemodialysis initiation by comparing intradialytic hemodynamic changes between patients treated at two separate major academic teaching hospitals, one of which does and one which does not routinely administer mannitol during hemodialysis initiation.
This observational study was approved by the Partners Healthcare Institutional Review Board. Hemodialysis initiation for acute kidney injury or progressive chronic kidney disease was performed at dedicated units in Brigham and Women’s Hospital (BWH; 793 beds) or Massachusetts General Hospital (MGH; 1,057 beds), both in Boston, Mass., USA. Detailed data from the first three dialysis sessions were collected from consecutive patients initiating hemodialysis between March 22nd and December 14th, 2010. Complete data for two sessions were available in 96% of cases; complete data for 3 sessions were available for 79% of cases. There were no major differences in the proportion of missing data according to acuity of renal injury (p = 0.65), presence of diabetes (p = 0.35) or heart failure (p = 0.06). Per institutional protocol at MGH, mannitol was administered intravenously during the dialysis session at a dose of 25 g/h; patients at BWH did not receive mannitol. We excluded those requiring pressors and those transitioning from continuous renal replacement therapy. The final cohort consisted of 102 individuals (278 hemodialysis sessions; 91% were performed as an inpatient).
The primary outcome of interest was the decline in blood pressure during dialysis (predialysis BP – nadir intradialytic BP). Secondary outcomes included (1) the nadir intradialytic BP and (2) the development of an intradialytic hypotensive event (defined as a drop in SBP of >20 mm Hg or absolute SBP <90 mm Hg). Blood pressure was measured using DASH 4000 monitors (GE Medical Systems; www.gemedical.com) at MGH and the internal blood pressure module of Fresenius 2008K dialysis machines at BWH (Fresenius Medical Care North America, www.fmcna.com). Blood pressure measurements were acquired predialysis, postdialysis and every 15 min during the procedure. According to standard hospital protocols, all devices were calibrated on at least an annual basis.
The administration of mannitol during hemodialysis was the primary exposure of interest and was verified from nursing notes and hospital pharmacy records.
Fresenius 2008K dialysis machines and F180 membranes were used in all treatments (Fresenius Medical Care North America). Dialysis treatment parameters (time, blood and dialysate flow rate, dialysate composition and ultrafiltration rate) were prescribed at the discretion of the treating nephrologist. The dialysate sodium concentration was 140 mmol/l in 97.5% of sessions (only one treatment session had a fixed dialysate sodium concentration of >140 mmol/l); no patient was prescribed a sodium-modeling algorithm. Cooled dialysate was recorded in 6 sessions (35–36°C). The dialysis nurse assigned to each individual subject recorded hemodynamic parameters, treatment parameters, interventions and administration of medications/fluids on standard clinical dialysis run-sheets.
All study data were obtained via detailed paper chart and electronic medical record review. Demographic data including sex, race and age were recorded at dialysis initiation. Other variables of interest included antihypertensive medication use, comorbidities including diabetes mellitus and congestive heart failure; dialysis treatment and hemodynamic parameters; and laboratory test results (prior to each dialysis session). All laboratory tests were performed at the corresponding hospital clinical laboratory of each dialysis unit.
Continuous variables were examined graphically and recorded as means (± SDs) for normally distributed data, or medians (with inter-quartile ranges) for non-normally distributed data. Comparisons were made using t tests or Wilcoxon rank sum tests, as appropriate. Categorical variables were examined by frequency distribution, recorded as proportions and comparisons made using the χ2 test.
The association of mannitol use (vs. standard treatment) with hemodynamic outcomes of interest was examined by fitting generalized linear regression models, with and without adjustment for case mix. Each individual could potentially contribute data from three separate dialysis sessions; the use of a repeated measures design was therefore required, in which clustered variance estimates were used to account for non-independence of covariates within subject, thereby allowing more accurate estimation of the standard error related to our exposure of interest. Individual covariates were selected on the basis of clinical and biological plausibility, without use of probabilistic selection criteria. Logarithmic transformation was performed for outcomes of interest that were found to be non-normally distributed.
Effect modification of mannitol and outcome according to prespecified variables of interest (diabetes, heart failure and acuity of kidney disease) was assessed by the inclusion of cross-product terms. Nominal two-sided p values of <0.05 were considered statistically significant. Analyses were performed using SAS v9.2 (SAS Institute, Carey, N.C., USA) and STATA 10.0MP (College Station, Tex., USA).
The primary cohort consisted of 102 patients; 48 (47%; all at MGH) received mannitol during their initiation treatments; 54 (53%; all at BWH) did not receive mannitol. Mean age was 62.1 (±15.6) years, 44.1% were diabetic, 22.6% had a history of congestive heart failure. There were no differences between those who did and did not receive mannitol according to age, sex, race, diabetes, heart failure, serum sodium, serum creatinine, antihypertensive use or predialysis blood pressure at baseline. The mannitol group contained a greater proportion of patients who initiated hemodialysis for acute indications and had dialysis catheters, though these differences were not statistically significant (table 1). Modest clinical differences in session length, blood and dialysate flow were evident both between groups and according to dialysis session chronology (table 2).
There was no significant difference in the mean unadjusted predialysis SBP over the initiation sessions for those patients who received mannitol versus those who did not (p = 0.9), nor in the mean unadjusted intradialytic nadir SBP (p = 0.11). However, in case-mix-adjusted models (adjusted for age, sex, diabetes, congestive heart failure, catheter use and predialysis SBP), patients treated with mannitol had 5.4 mm Hg higher nadir intradialytic SBP compared to those who were not (p = 0.03; table 3). In exploratory models, additional adjustment for predialysis sodium, predialysis weight, acuity of kidney disease, UF volume, session length, blood flow and dialysate flow resulted in accentuation of the effect estimate (8.2 mm Hg higher nadir SBP with mannitol; p = 0.01).
Systolic BP decline (predialysis SBP – SBP nadir) was considered as a log-transformed variable due to non-normal distribution. Individuals treated with mannitol had 30.0% and 25.1% less decline in log SBP in unadjusted (p = 0.02) and adjusted (p = 0.03) analyses, respectively. In exploratory models, additional adjustment for predialysis sodium, predialysis weight, acuity of kidney disease, UF volume, session length, blood flow and dialysate flow demonstrated that mannitol use was associated with 27% less decline in log SBP (p = 0.047). There was no evidence for effect modification according to the presence of diabetes, heart failure or acuity of kidney disease (p-interaction >0.10).
Overall, 51% of sessions were complicated by a hypotensive event, defined in this study as a drop of 20 mm Hg in SBP or absolute SBP <90 mm Hg. In adjusted models (age, sex, diabetes, congestive heart failure, catheter use and predialysis SBP), patients treated with mannitol had 50% lower odds of experiencing hypotensive events (OR 0.50; 95% CI 0.29–0.83). In exploratory models, upon additional adjustment for predialysis sodium, predialysis weight, acuity of kidney disease, UF volume, session length, blood flow and dialysate flow, the effect estimate was accentuated and remained significant (OR 0.32; 95% CI 0.14–0.74; fig. 1).
In further sensitivity analyses, after modifying the definition of a hypotensive event (drop in SBP of >40 mm Hg or absolute SBP nadir <90 mm Hg; which occurred in 28% of sessions), the use of mannitol remained associated with lower case-mix-adjusted odds of developing a hypotensive event (OR 0.35; 95% CI 0.18–0.66).
In this study, we have leveraged institutional differences between two large academic teaching hospitals during hemodialysis initiation to explore the effects of hypertonic mannitol on intradialytic hemodynamic parameters. We found that patients who receive hypertonic mannitol during hemodialysis initiation have: (1) higher nadir SBP during dialysis, (2) less decline in SBP during hemodialysis, and (3) lower odds of experiencing intradialytic hypotensive events.
The role of osmolality in the genesis of dialysis disequilibrium and hemodynamic sequelae has been hypothesized for many decades, with supportive evidence initially coming indirectly from clinical observations. Early dialysis treatments utilized a low dialysate sodium concentration (∼127 mmol/l) in order to facilitate sodium removal . However, with the implementation of pressure-driven ultrafiltration (which allowed volume removal in a controlled fashion over shorter periods of time) many patients developed adverse effects that were ameliorated by raising the dialysate sodium concentration from ∼127 to ∼140 mmol/l . This concept was further developed by the use of fixed higher dialysate sodium concentrations  and sodium modeling algorithms [17,18], which were purported to preserve intravascular volume and promote intradialytic hemodynamic stability. Older literature and clinical experience confirmed the beneficial effects of hypertonic saline, hypertonic glucose and hypertonic mannitol in the treatment of dialysis-related cramps .
There are sound physiological hypotheses as to why osmolality could influence hemodynamic stability during hemodialysis. A study in which hemodynamic stability was challenged (by removal of 2–3% body weight over 2 h during various investigational dialytic protocols), confirmed a marked decline in measured plasma osmolality during the course of hemodialysis, and noted a close correlation with the decline in mean arterial pressure (MAP). In addition to standard hemodialysis, a decline in osmolality was also observed under the experimental conditions of isokalemic dialysis and with the use of isotonic mannitol. However, no significant osmolality changes (nor changes in MAP) were noted with the protocols utilizing isolated ultrafiltration or hypertonic mannitol, supporting an association between preservation of osmolality and hemodynamic stability . Left unanswered by this study is the mechanism by which higher osmolality was associated with improved hemodynamic stability. To address this, Shimuzi et al.  studied the hemodynamic and biochemical effects of infusions of 10% saline, 50% glucose, 0.9% saline or arginine vasopressin (AVP) during intradialytic hypotensive episodes. The investigators found that hypertonic saline infusion increased plasma osmolality (292–302 mosm/kg; p < 0.001), plasma AVP (3.9–7.8 pg/ml; p = 0.03) and MAP (66.6–71.8 mm Hg; p = 0.01). Although they did detect an increase in plasma volume with hypertonic saline, they postulated the magnitude (2.3%) of the rise was not sufficient to explain the corresponding increase in MAP; instead they hypothesized a role for a vasopressive effect of AVP in blood pressure maintenance. The authors replicated their findings in a subsequent study , while other investigators have reported that subjects with IDH were unable to appropriately increase AVP levels in response to hemodynamic stressors . A further study demonstrated that infusion of AVP alone improved cardiovascular stability during dialysis, thus lending additional evidence regarding its role in the maintenance of vascular tone .
We found that mannitol administration led to improved hemodynamic stability during dialysis according to a number of different metrics, including change in systolic blood pressure, nadir blood pressure and development of hypotensive events (SBP decline >20 mm Hg or absolute SBP <90 mm Hg). Our findings extend previous reports as we specifically examined the period of dialysis initiation, when the decline in osmolality caused by dialysis is perhaps greatest.
The prevention of hypotensive events deserves to be a major quality improvement target in hemodialysis, given the association with the development of cerebral atrophy , myocardial dysfunction , and increased long-term mortality . Myocardial blood flow studies have detected reduced myocardial perfusion associated with hemodialysis itself . It is possible that the phenomenon of myocardial stunning, exacerbated by intradialytic hypotension, may contribute to the unacceptably high 90-day mortality rate  noted with hemodialysis initiations; further studies are required to investigate this possibility. There were no apparent major adverse effects of mannitol administration, though this was not systematically studied. Potential concerns may include the precipitation of pulmonary edema by mannitol, though this might be offset by better toleration of ultrafiltration. Given the potential concern for mannitol-induced acute kidney injury , future trials should consider measurement of residual blood mannitol levels and perform detailed examination of renal recovery between treatment arms.
A significant strength of this study was the ability to control for individual subject-level characteristics across both clinical sites. In this regard we were able to circumvent the potential pitfall of ecological fallacy, where individual members of a group are erroneously assumed to have the average characteristics of that group. We purposefully took advantage of differences in institutional protocols that allowed us to examine mannitol administration as our primary exposure of interest; in some ways this was comparable to a quasi-randomized trial design. However, without the primacy of actual randomization, we were particularly cognizant to adjust for potential differences in subject characteristics between the two centers. The lack of major differences in baseline characteristics, and statistical significance of results after adjustment for potential confounders, argues against differences in disease severity or co-morbidities as explanations for our findings.
There are several limitations of this study that merit further discussion. Limitations inherent to observational studies remain, including the potential for residual confounding based on incomplete adjustment of variables considered or from those not considered at all; of note, it is less likely that our results suffer from confounding by indication, as the initiation protocols implemented at each institution largely remove the influence of patient and physician-related factors in the decision to use mannitol. It is possible that other unmeasured differences in physician and/or nursing practice patterns, or unmeasured patient characteristics between the two institutions may account for our findings. For example, MGH has the ability to perform continuous intradialytic blood volume monitoring, whereas BWH does not. Blood volume monitoring was not found to be associated with a reduction in intradialytic hypotension in a previous randomized controlled trial . Data limitations precluded us from determining the proportion of patients in whom blood volume monitoring was actually utilized and whether medical interventions occurred secondary to changes in blood volume monitoring itself. However, assuming the clinical response to blood volume monitoring would lead to alterations in achieved ultrafiltration, we did not detect attenuation of effect estimates after additional adjustment for ultrafiltration, arguing against a role for blood volume monitoring as a major confounder of our findings. A notable feature of this study was the inclusion of subjects with both acute and chronic indications for renal replacement therapy. We tested for (and excluded) effect modification based on the acuity of kidney disease. However, we recognize that these may be distinct pathophysiological processes in terms of volume homeostasis and hemodynamic stability. Overall, our sample size was modest and due to data collection limitations, we were unable to delineate the timing of hypotensive events and other associated patient symptoms at a more granular level. Generalizability may be limited because all patients were treated in two large academic teaching hospitals, in the setting of dialysis initiation.
In conclusion, our comparison of hemodynamic patterns between patients at two institutions that differ in the use of hypertonic mannitol for hemodialysis initiation suggests that hypertonic mannitol may help to prevent excessive intradialytic blood pressure decline. Additional interventional studies are required to confirm our findings in dialysis initiation, systematically assess for potential adverse effects and to investigate potential therapeutic extension to the chronic hemodialysis setting.
The authors wish to gratefully acknowledge the assistance of Dr. Nina Tolkoff-Rubin MD, Dr. Steven Brunelli MD MSCE, Ms. Nyla Shellito RN, Ms. Susan Taylor RN, Ms. Katherine Serge RN and Ms. Gail Appling for facilitating the completion of this study.
Portions of this work were accepted in abstract form for the National Kidney Foundation Spring Clinical Meeting, 2012.
This work was conducted with support from the Scholars in Clinical Science Program of Harvard Catalyst, The Harvard Clinical and Translational Science Center (Award No. UL1 RR025758 and financial contributions from Harvard University and its affiliated academic health care centers). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, the National Center for Research Resources, or the National Institutes of Health.
Dr. McCausland is supported by a research fellowship from the National Kidney Foundation (2011–13).
Dr. Waikar is supported by DK075941 and UO1DK085660.
Finnian McCausland, MB, BCh
MRB-4, Brigham and Women’s Hospital
Boston, MA 02446 (USA)
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.